Allergan's Trivaris approved to treat retinal diseases

Allergan, Trivaris, retinal diseases, vision loss, ocular

Trivaris (triamcinolone acetonide injectable suspension) 80 mg/mL is a new anti-inflammatory drug from Allergan to treat retinal diseases that can result in vision loss. A synthetic glucocorticoid corticosteroid, the product is an intravitreal shot that treats sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. The Irvine, Calif., firm said the introduction marks its first product for back-of-the-eye diseases.

To see more Daily News articles, click here.

To go to the Drug Topics homepage, click here.